Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Terlipressin Infusion for HRS-AKI (INFUSE)
NCT04460560Phase 3Completed
- Sponsor
- University of Pennsylvania
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of terlipressin in hepatorenal syndrome (HRS), sponsored by University of Pennsylvania. Primary endpoint: Improvement of Serum Creatinine at 14 days. Started Dec 2020; status: completed.
02
Drugs
terlipressin
03
Conditions
hepatorenal syndrome (HRS)
Beyond the preview
Go deeper on NCT04460560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04460560.